Toral-Martiñón René, Shkurovich-Bialik Paul, Collado-Corona Miguel Angel, Mora-Magaña Ignacio, Goldgrub-Listopad Shani, Shkurovich-Zaslavsky Mario
Departamento de Investigación en Audiología y Neurofisiología, Instituto de la Comunicación Humana, Centro Nacional de Rehabilitación, Secretaría de Salud, Mexico City, Mexico.
Arch Med Res. 2003 May-Jun;34(3):205-8. doi: 10.1016/S0188-4409(03)00022-5.
Cisplatin is a widely used chemotherapy agent that has several adverse effects, such as ototoxicity. Evaluation of hearing loss due to cisplatin therapy in children is difficult. The purpose of this study was to compare the validity of distortion product otoacoustic emissions (DPOAEs) with pure tone audiometry (PTA) in assessing hearing loss in children under cisplatin therapy.
We reviewed the files of 26 children aged between 2 and 15 years; 14 were girls. All were under treatment with cisplatin for malignancy. PTA and DPOAEs were obtained at the same session. Three subjects were studied twice; thus, there were 29 sets of studies.
Determining a cut-off point at 45 dB HL for PTA and 4 dB SPL difference for DPOAEs, diagnostic specificity for the latter was 0.97 while sensitivity was 0.57.
DPOAEs represent a highly valuable test for evaluating hearing loss due to cisplatin treatment. DPOAEs is a quick and objective hearing assessment method not requiring much cooperation from children.
顺铂是一种广泛使用的化疗药物，有多种不良反应，如耳毒性。评估顺铂治疗导致儿童听力损失较为困难。本研究的目的是比较畸变产物耳声发射（DPOAE）与纯音听力测试（PTA）在评估接受顺铂治疗儿童听力损失方面的有效性。
我们回顾了26名年龄在2至15岁之间儿童的病历；其中14名是女孩。所有儿童均因恶性肿瘤接受顺铂治疗。在同一时段进行PTA和DPOAE测试。对3名受试者进行了两次研究；因此，共有29组研究。
将PTA的截断点设定为45 dB HL，DPOAE的截断点设定为4 dB SPL差值时，后者的诊断特异性为0.97，而敏感性为0.57。
DPOAE是评估顺铂治疗所致听力损失的一项非常有价值的测试。DPOAE是一种快速且客观的听力评估方法，不需要儿童太多配合。
